Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Schedule of Potentially Antidilutive Shares Excluded from Computation of Diluted Net Loss Per Share

Potentially anti-dilutive shares excluded from the calculation of diluted net loss per share for the three and six months ended June 30, 2024 include the following:

Private warrants	4,721,533
Working capital warrants	523,140
Public warrants	3,432,286
PIPE warrants	10,209,994
Stock options	4,248,176
SPA warrants	1,000,000
Senior convertible notes shares	1,000,000
Deferred founder shares (1)	1,173,631
2024 convertible promissory notes	5,044,382
2024 convertible promissory note warrants	5,830,929
Convertible bridge loans	18,637
Convertible bridge loan warrants	1,272,000
Liability-classified consideration shares	2,847,661
Tranche right derivatives	5,393,914
Total	46,716,283

(1)As described in Note 8, Related Party Transactions, deferred founder shares do not have voting rights, do not participate in dividends and are not transferable absent the Company’s consent. Therefore, while deferred founder shares are considered outstanding for legal purposes and are included in the total quantity of outstanding shares on the unaudited condensed consolidated statements of stockholders’ deficit, they are not considered outstanding for accounting purposes, including basic and diluted net loss per share purposes.